WallStSmart

Abbott Laboratories (ABT)vsLive Nation Entertainment Inc (LYV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 76% more annual revenue ($44.33B vs $25.20B). ABT leads profitability with a 14.7% profit margin vs 2.0%. ABT appears more attractively valued with a PEG of 1.52. ABT earns a higher WallStSmart Score of 51/100 (C-).

ABT

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 7.3Quality: 4.8
Piotroski: 3/9

LYV

Hold

47

out of 100

Grade: D+

Growth: 5.3Profit: 5.5Value: 4.0Quality: 3.8
Piotroski: 3/9Altman Z: 1.46
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-315.5%)

Margin of Safety

-315.5%

Fair Value

$25.23

Current Price

$104.83

$79.60 premium

UndervaluedFair: $25.23Overvalued

Intrinsic value data unavailable for LYV.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT3 strengths · Avg: 8.3/10
Market CapQuality
$180.82B9/10

Large-cap with strong market position

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

LYV1 strengths · Avg: 10.0/10
Return on EquityProfitability
36.7%10/10

Every $100 of equity generates 37 in profit

Areas to Watch

ABT4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

LYV4 concerns · Avg: 2.5/10
Profit MarginProfitability
2.0%3/10

2.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
7.472/10

Expensive relative to growth rate

Price/BookValuation
133.6x2/10

Trading at 133.6x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : LYV

The strongest argument for LYV centers on Return on Equity. Revenue growth of 11.1% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : LYV

The primary concerns for LYV are Profit Margin, Piotroski F-Score, PEG Ratio. Thin 2.0% margins leave little buffer for downturns.

Key Dynamics to Monitor

LYV carries more volatility with a beta of 1.15 — expect wider price swings.

LYV is growing revenue faster at 11.1% — sustainability is the question.

ABT generates stronger free cash flow (2.6B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABT scores higher overall (51/100 vs 47/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Live Nation Entertainment Inc

COMMUNICATION SERVICES · ENTERTAINMENT · USA

Live Nation Entertainment, Inc is an American global entertainment company, founded in 2010, following the merger of Live Nation and Ticketmaster. The company promotes, operates, and manages ticket sales for live entertainment in the United States and internationally. It also owns and operates entertainment venues, and manages the careers of music artists.

Want to dig deeper into these stocks?